# A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

> **NCT04951622** · PHASE3 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 199 (estimated)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** Nipocalimab
- **DRUG:** Placebo
- **DRUG:** Nipocalimab SC-LIV

## Key facts

- **NCT ID:** NCT04951622
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-15
- **Primary completion:** 2023-11-17
- **Final completion:** 2029-03-30
- **Target enrollment:** 199 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951622, "A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04951622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*